Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bocxman-would like to chat with you and send you something-can you have the administrator contact me with your phone or email address? Thanks, Scouty
I will forgive your subtle errors of syntax and spelling and attribute them to the brown water you are consuming...but, once again, a great post for reasons to stick with this interesting play...why, I may share it with Ricardo....
now...that is a great post.....and I don't say this often.....
I tried by phone and email to speak with Dr Swartzentruber, with no luck-it would be very interesting if you could establish a contact and have him provide information and validation of the ongoing work with biocurex-Dr Moro mentioned to me that the work with Goshen was largely centered in the radiology divisions there--
Recaf is present in the blood of healthy patients, and is not just sloughed off by cancer cells, so "Kag's" messages aren't just to pester you "Box". In fact, pregnant patients would need to be screened and excluded from routine testing, according to Dr Moro (rapid cell division of any sort triggers higher levels of recaf)-but, this isn't fatal to the utility of the recaf test, obviously, for many reasons..
doing fine here in NC steeltown/Tim--get ready for tko!
I've had a series of nice communications with Dr Moro-the following is one recent comment from this delightful and engaging gentleman: "Nobody really knows what is going on with the market, but perhaps the MM are covering their shorts in the way up a few weeks ago. This is illegal, since they have to cover shorts within 72 hours, but I am told everybody does it.
Our Company is unusual in the sense that it is not managed as a promotional BB or pink sheets stock. We want to create long term value and I know the technology very well and it works. I certainly believe that sooner or later (let us hope that sooner) RECAF tests will be a common medical prescription and that is why I, and our team, keep working in that direction. Time will tell how that reflects on the market price. I remember once, to my dismay, following a good press release related to the technology resulted in a drop of the share price... Go figure."
Regards, Ricardo
I have carefully explored the subject of the pink sheet status of bocx with Dr Moro - the company responds to nasdaq inquiries diligently, with additional questions coming which seem obscure and dilatory-the company is patiently and honestly responding and, it is the thinking, the inquiries will eventually cease...the prospects of a small company on the cusp of a simple cancer detection test(which is actually a test that picks up on recaf, the product of rapid cell division and death and not just limited to malignancies) is a bit much for the inquiring minds at nasdaq to accept, is the impression I get from Ricardo Moro (who by the way is a delightful and sincere sounding person to talk to-heck, I may just pay him a personal visit this summer-Vancouver is a great place to visit).....
too much bickering here, thank you....if someone could post 5 logical, specific questions (not seeking to discover timing of announcements, inside information, etc.), I will be happy to get and post the answers-there are lots of intelligent observations and questions-can kag and boxman drop the gloves and formulate a set of questions, the answers of which might be helpful..I think Dr Moro would accomodate....scouty
what if abbott, or some other company, doesn't want this type of information out...why wouldn't they want it out...because the price of the purchase or deal.....would be...too pricey...I don't know, but business is cutthroat stuff, and even those awash with financial power, e.g., walmart or some other such giant, are well known to be brutal even when they have a good deal...food for thought.....
a1derfullife (great name by the way)...the process of lighting up the errant cells with a fragmnet of radioactive anitbody is something Dr Moro mentioned in our conversation, but some of it must have escaped me-your explaination makes great sense and if bocx could do this, it would be too good to be true---scouty
I hear you loud and clear Half Full Glass-just to play the devil's advocate-why are all the neighborhood "whole body ct scans", "stayhealthy" ct scans probing for cancer going belly up? A simple, painless, not too expensive diagnostic study condemned by many in the health profession....and, the big question on this particular investment-why no independent verification of the accuracy and why aren't "they" beating the doors down to get in and partner up with bocx? Who knows, maybe "they" are........
Good points, but if you take millions of patients who may have cancer diagnoses (via recaf) every year, patients who are asymptomatic, unaffected in any measurable way (yes I know this will sound bizzare)and who are then given the kiss of death.... "I am sorry to report that you have some sort of malignancy, and this test you took makes us duty bound to evaluate every potential source of it, be damned the risks and expense... and, shall we first begin with a full laboratory series and then a whole body ct (feel good scan) to look for the errant host tumor....but, however, these diagnostic studies may show up a lot of cystic/benign growths too, but we must evaluate each and every one of these,for we know not which produced the microscopic serum based evidence via recaf... some of these lesions may be deep within the brain, but a painless biopsy using a long needle under fluoroscopic or ct guidance (or a quite expensive mri and P.E.T sequence) is the next order of business..then, of course, we must be vigilant for the iatrogenic mishaps that do, regrettably, occur with invasive procedures; and,of course, misreads are occasionally present in the best of hands, but then that is an acceptable risk, no?".......and on and on....and you get the picture of the system being overcome and the cost-benefit analysis clouded..Combining the recaf test with another accepted test is probably the way to go to lend validity to the biocurex solution (but of course wouldn't the kind- hearted insurance industry wish to have a blanket test to "deinsure" those who have a piece of presumed tumor cell floating around in their blood..interesting situation.....
I too have discussed this science with an oncology expert. What's to prevent a "witch hunt" from occuring when a serum positive result is obtained via uptake from an antibody and the afp receptor? This is one issue I meant to discuss with Dr Moro recently--can the blood test determine from what source(cancerous) the sloughed off cells come from? From prostate, breast, etc., or do you then need a tissue sample from a source that needs to be independently verified? Thus, the issue of multiple, hysterical tests and invasive diagnostic procedures.....the recent prostate commentary from the company sounded like a positive statement on the serum test alone being able to differentiate the likely tumor source, which made my contact/dear friend, professor emeritus and all, surmise that, if true, the biocurex blood test along with a psa would be a compelling union of two simple tests...food for thought-perhaps someone on the board can enlighten all on the ability of the serum test to identify cell type.....scouty
I wish I had had the time and knowledge to ask the right questions, but it was more of a friendly chat, just verifying in my mind certain things and getting him to talk and reveal his personality-much like a seasoned detective getting a suspect to talk freely, although I'm not much of a detective....
I have spent some time today researching biocurex, pulling up the patent acquired on 2/04/03 ("Detection of Cancer Using Antibodies to the Alphafeto Protein receptor"), cross checking a few items and then speaking with a rather delightful sounding founder, Ricardo Moro, MD, who was kind enough to speak with me at some length. He is very measured and steadfast with his approach and has apparently dedicated his life (and resources) to the company. He is not one to push out pr after pr, but will plug along with his process (with what appears to be a very broad patent) to identify, target, and treat a variety of cancer cells. He is not worried about money right now at all. I get the sense he will be patient and let the smart money come to him...with the use of radioactive assays in this world environment of security concerns, the process has been much slower than anticipated, but to me, he's a determined, caring and confident scientist who's background (which I checked somewhat) fits right into this remarkable science. Scouty
online A–Z of cancer genes mutations
20 March 2004
Building on the cancer gene census, the Cancer Genome Project team has also embarked on the ambitious task of cataloguing all the mutations in the genes that have been associated with cancer. The first fruits of their labours, the online database COSMIC (catalogue of somatic mutations in cancer), was launched in February 2004.
A huge body of information has accumulated about the different mutations affecting these genes. Currently, researchers have to go to many different sources to gather this data. A single, coherent and comprehensive resource – an A–Z of cancer genes and their mutations – will be an invaluable resource in cancer genetics and cancer biology.
The first phase of COSMIC includes data on four genes – BRAF, HRAS, KRAS2 and NRAS – and the scale of the task is already clear. Take the KRAS2 gene, for example: over the years, more than 35 000 tumours have been tested, more than 8000 mutations have been found, and they were reported in more than 700 papers.
COSMIC already holds information on 57 444 tumours and reports a total of 10 647 mutations. Ultimately, however, it will include information on all genes that are somatically mutated in human cancer.
For further information visit the COSMIC database and website.
http://www.wellcome.ac.uk/doc_WTX031289.html>
<http://snipurl.com/qhbk>
Quite comprehensive website gathering virtually every conceivable research issue on cancer-I'm looking for references to the recaf cell/tissue/mutation..perhaps the research guru's can help-scouty
Here's a list of the current breast cancer clinical trials and collaborations with drug companies from the cancer center at Goshen Cancer Center (a center referred to in Biocurex archives as being in collaboration with the company):Treatment Trials / Breast Cancer
NSABP B-35: A clinical trial comparing Anastrozole with Tamoxifen, taken for five years, in postmenopausal women with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy. This double-blind study will evaluate the effectiveness in preventing the subsequent occurrence of breast cancer.
CTSU/ECOG/SWOG S0012: A clinical trial to compare response rates in patients with inflammatory and locally advanced breast cancer treated with weekly Doxorubicin and daily oral Cyclophosphamide given with G-CSF support followed by weekly Paclitaxel for 12-weeks, to that in patients treated with the standard Doxorubicin and Cyclophosphamide regimen given every 3 weeks by Paclitaxel for 12-weeks.
NSABP B-36: A clinical trial of adjuvant therapy comparing 6 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to 4 cycles of Adriamycin and Cyclophosphamide (AC) with or without Celecoxib with node-negative breast cancer. The primary aim is to determine if one regimen is superior in prolonging disease free survival.
NSABP B-38: The primary aim of this study for women with node-positive breast cancer are to determine whether a regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel and gemcitabine (DD AC→PG) will be superior to a regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) as well as to a regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel alone (DD AC→P) in improving disease-free survival (DFS) and to compare the relative DFS of TAC and DD AC→P.
INTERNAL CCC BRE 0-6710: Mammary Ductoscopy and Intraductal Biopsy for Women at High Risk for Developing Breast Cancer – A Post Market Registry
INTERNAL CCC BRE 0-6711: Mammary Ductoscopy and Intraductal Biopsy for Women Presented with Spontaneous Nipple Discharge – A Post Market Registry
CTSU/ECOG/NCIC MA-27: A randomized Phase III Trial of Exemestane versus Anastrozole with or without Celecoxib in Postmenopausal Women with Receptor Positive Pimary Breast Cancer. Adjuvant chemotherapy and radiation are allowable. Treatment is for 5 years.
Scouty |
Boxman-your opinions carry this board, it seems-if biocurex is a stock that can make one "sensational money" in advance of wall street recognition, could you (as a means of reassurance of your opinions on bocx) set out some of the companies you've discovered with your due diligence which panned out(like we hope bocx will)? I know this is a personal question, but the door was opened on your end..this isn't a dig at you at all, for we all may profit from your insight..thanks, Scouty
Half Full Glass-I had the same thoughts, and I had some concern that the stock didn't move with the Abbott news and the "progress" report issued recently by the company-searching the archives for the company, it is at different times in years past noted to be a Texas company, a Nevada(Las Vegas) company, a California company and the toll free number evidently stayed the same, typical of canadian pink sheet companies-makes one suspicious--the Japanese group who tested recaf, evidently, were surprised and pleased with the blind study (tissue samples submitted and the company accurately id'd the various tumor cell types) which occurred two or three years ago, but if it actually happened, what happened with that quite positive event? The Goshen Hospital System in Indiana was reportedly working with the company, but no news at all from that well known cancer center-I've spoken with a company official-very accomodating and open and obviously very intelligent (and very positive sounding)-I am going to try and contact the surgical oncologist, Dr Swartzenturber, who is associated with Goshen and see what he might have to say and I'll be happy to report (although I am doubtful that he'd be as accomodating as Dr Whittenberg)..the recaf identification is almost too good to be true, but if it is, why aren't the big names beating on biocurex's door (or are they)....interesting situation here...Scouty
I did send you a message but it didn't go through-see tko msg board to you-would like to chat with you--scouty (walrus has my email address) scouty
Welcome me or not, here I am-found this intriguing company recently on a post on another board from an ihub poster on this board-he was surly, condescending, doubtful, a true skeptic on the other board--just the things you need to be interested when he's putting his dollars into a play, in this case, biocurex...I always thought curing cancer was alot easier than the billions of dollars of research suggested-let's see, cancer cells start from normal cells and they begin to divide rapidly..this increased cell division-measured by some as "tumor doubling time"-represents a dramatic metabolic activity that should "lite up" with our modern scientific capabilities...why, just spread a coat over all cells (with a test),or make the coat attach only to the hyperactive cells, and see which ones lite up on a process which identifies increased cell division.....viola! early detection! Am I being too optimistic? Is this the company that can do it? Are there other, bigger names, that are way ahead of biocurex? Why in the heck, with the recent announcement of the accuracy of the test for early detection of breast cancer, didn't this stock zoom? Is there some toxic financing or outrageous dilution situation looming with warrant deluge? I've reviewed the posts and happy to be on board! Scout